×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CDXC – chromadex corporation (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CDXC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/8
11:07 pm
cdxc
ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/8
01:50 pm
cdxc
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]
Low
Report
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]
11/8
08:56 am
cdxc
5 Stocks With Recent Price Strength to Tap Wall Street Rally [Yahoo! Finance]
Medium
Report
5 Stocks With Recent Price Strength to Tap Wall Street Rally [Yahoo! Finance]
11/7
08:34 am
cdxc
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide [Yahoo! Finance]
Low
Report
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide [Yahoo! Finance]
11/7
08:32 am
cdxc
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
Medium
Report
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
11/7
06:58 am
cdxc
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality [Yahoo! Finance]
Low
Report
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality [Yahoo! Finance]
11/6
01:10 pm
cdxc
ChromaDex Co. (NASDAQ: CDXC) had its price target raised by analysts at Roth Mkm from $6.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
ChromaDex Co. (NASDAQ: CDXC) had its price target raised by analysts at Roth Mkm from $6.00 to $8.00. They now have a "buy" rating on the stock.
11/5
11:04 am
cdxc
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? [Yahoo! Finance]
Low
Report
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/8
04:48 pm
cdxc
Form 3 ChromaDex Corp. For: Nov 07 Filed by: Lopez Carlos Luis
Medium
Report
Form 3 ChromaDex Corp. For: Nov 07 Filed by: Lopez Carlos Luis
10/31
04:02 pm
cdxc
Form 8-K ChromaDex Corp. For: Oct 31
High
Report
Form 8-K ChromaDex Corp. For: Oct 31
10/31
04:01 pm
cdxc
Form 10-Q ChromaDex Corp. For: Sep 30
High
Report
Form 10-Q ChromaDex Corp. For: Sep 30
10/23
05:04 pm
cdxc
Form 4 ChromaDex Corp. For: Oct 21 Filed by: Pamir Ozan
Low
Report
Form 4 ChromaDex Corp. For: Oct 21 Filed by: Pamir Ozan
10/23
05:03 pm
cdxc
Form 3 ChromaDex Corp. For: Oct 21 Filed by: Pamir Ozan
Low
Report
Form 3 ChromaDex Corp. For: Oct 21 Filed by: Pamir Ozan
10/11
04:00 pm
cdxc
Form 8-K ChromaDex Corp. For: Oct 08
Medium
Report
Form 8-K ChromaDex Corp. For: Oct 08
9/20
08:33 am
cdxc
Form 8-K ChromaDex Corp. For: Sep 19
Low
Report
Form 8-K ChromaDex Corp. For: Sep 19
8/26
07:07 pm
cdxc
Form 4 ChromaDex Corp. For: Aug 23 Filed by: Patrick Kristin
Low
Report
Form 4 ChromaDex Corp. For: Aug 23 Filed by: Patrick Kristin
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Form CT ORDER ChromaDex Corp.
12.8%
4/20 ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR) 11.2%
8/14 ChromaDex Announces $7 Million Private Placement of Common Stock 10.3%
11/20 European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food 8.0%
2/27 Form 4 ChromaDex Corp. For: Feb 25 Filed by: Jaksch Frank L Jr 7.8%
11/12 Form 8-K ChromaDex Corp. For: Nov 12 7.4%
3/10 Q4/2019 12/31/2019 EPS -0.110 ZacksConsensus -0.120 ActVsEst 0.010 - Beat 7.3%
10/15 Chromadex Corp (NASDAQ: CDXC) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 7.3%
1/6 First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension 6.8%
4/2 Form CT ORDER ChromaDex Corp. 6.5%
4/20 ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR) 11.2%
8/14 ChromaDex Announces $7 Million Private Placement of Common Stock 10.3%
11/20 European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food 8.0%
2/27 Form 4 ChromaDex Corp. For: Feb 25 Filed by: Jaksch Frank L Jr 7.8%
11/12 Form 8-K ChromaDex Corp. For: Nov 12 7.4%
3/10 Q4/2019 12/31/2019 EPS -0.110 ZacksConsensus -0.120 ActVsEst 0.010 - Beat 7.3%
10/15 Chromadex Corp (NASDAQ: CDXC) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 7.3%
1/6 First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension 6.8%
4/2 Form CT ORDER ChromaDex Corp. 6.5%
TOP News Decliners
11/4
ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
-15.5%
2/25 ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020 -15.0%
3/17 Chromadex Corp (NASDAQ: CDXC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -14.5%
5/28 Chromadex Corp (NASDAQ: CDXC) was given a new $7.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -9.3%
3/31 Form 3 ChromaDex Corp. For: Mar 27 Filed by: Jordan Megan Kern -8.0%
12/16 ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen® -7.4%
3/23 Cellular Health Market Leader Tru Niagen® Launches Online in Australia -7.3%
1/10 Form 8-K ChromaDex Corp. For: Jan 07 -6.6%
10/1 Chromadex Corp (NASDAQ: CDXC) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -5.8%
11/12 ChromaDex Corporation (CDXC) Q3 2019 Earnings Call Transcript [The Motley Fool] -5.6%
2/25 ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020 -15.0%
3/17 Chromadex Corp (NASDAQ: CDXC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -14.5%
5/28 Chromadex Corp (NASDAQ: CDXC) was given a new $7.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -9.3%
3/31 Form 3 ChromaDex Corp. For: Mar 27 Filed by: Jordan Megan Kern -8.0%
12/16 ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen® -7.4%
3/23 Cellular Health Market Leader Tru Niagen® Launches Online in Australia -7.3%
1/10 Form 8-K ChromaDex Corp. For: Jan 07 -6.6%
10/1 Chromadex Corp (NASDAQ: CDXC) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -5.8%
11/12 ChromaDex Corporation (CDXC) Q3 2019 Earnings Call Transcript [The Motley Fool] -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: